Abstract
Background: In 2015 the results of a large meta-analysis on the use of adjuvant bisphosphonates in early breast cancer (EBC) were practice changing. The data showed that in postmenopausal women bisphosphonates resulted in an absolute improvement in breast cancer mortality.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have